GWAS studies have even identified risk association with genes that are important for current and new MS therapies including vascular cell adhesion molecule 1 (VCAM1), as well as genes related to the crucial environmental factor vitamin D [65]. This evidence concerns the gene VCAM1 and myeloid sarcoma.